25 XP   0   0   10

Biotest Aktiengesellschaft
Buy, Hold or Sell?

Let's analyse Biotest together

PenkeI guess you are interested in Biotest Aktiengesellschaft. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Biotest Aktiengesellschaft. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Biotest Aktiengesellschaft

I send you an email if I find something interesting about Biotest Aktiengesellschaft.

Quick analysis of Biotest (30 sec.)










What can you expect buying and holding a share of Biotest? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
47.5%

What is your share worth?

Current worth
€12.61
Expected worth in 1 year
€15.59
How sure are you?
47.5%

+ What do you gain per year?

Total Gains per Share
€2.99
Return On Investment
10.3%

For what price can you sell your share?

Current Price per Share
€28.90
Expected price per share
€22.80 - €30.40
How sure are you?
50%

1. Valuation of Biotest (5 min.)




Live pricePrice per Share (EOD)

€28.90

Intrinsic Value Per Share

€24.07 - €100.64

Total Value Per Share

€36.68 - €113.25

2. Growth of Biotest (5 min.)




Is Biotest growing?

Current yearPrevious yearGrowGrow %
How rich?$531.6m$385.9m$62.5m13.9%

How much money is Biotest making?

Current yearPrevious yearGrowGrow %
Making money$41.2m-$8.4m$49.6m120.5%
Net Profit Margin15.7%-6.7%--

How much money comes from the company's main activities?

3. Financial Health of Biotest (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#104 / 1009

Most Revenue
#72 / 1009

Most Profit
#55 / 1009

Most Efficient
#89 / 1009

What can you expect buying and holding a share of Biotest? (5 min.)

Welcome investor! Biotest's management wants to use your money to grow the business. In return you get a share of Biotest.

What can you expect buying and holding a share of Biotest?

First you should know what it really means to hold a share of Biotest. And how you can make/lose money.

Speculation

The Price per Share of Biotest is €28.90. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biotest.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biotest, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €12.61. Based on the TTM, the Book Value Change Per Share is €0.75 per quarter. Based on the YOY, the Book Value Change Per Share is €-0.62 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biotest.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps1.043.6%1.334.6%-0.08-0.3%0.080.3%0.100.3%
Usd Book Value Change Per Share1.053.6%0.802.8%-0.66-2.3%0.000.0%0.030.1%
Usd Dividend Per Share0.000.0%0.000.0%0.010.0%0.010.0%0.010.1%
Usd Total Gains Per Share1.053.6%0.802.8%-0.65-2.3%0.010.0%0.050.2%
Usd Price Per Share33.03-33.59-37.16-31.24-65.50-
Price to Earnings Ratio7.95-9.73--25.05--25.06--647.23-
Price-to-Total Gains Ratio31.45-14.88--26.79--34.18--37.37-
Price to Book Ratio2.46-3.03-3.70-2.70-5.28-
Price-to-Total Gains Ratio31.45-14.88--26.79--34.18--37.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share30.79584
Number of shares32
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share0.800.00
Usd Total Gains Per Share0.800.01
Gains per Quarter (32 shares)25.460.39
Gains per Year (32 shares)101.821.55
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10102922-0-8
202041943-0-6
303052965-0-4
404073987-0-2
505095008-10
6061160210-12
7071370412-14
8081580613-16
9091690815-18
1001018101017-110

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%5.07.00.041.7%6.014.00.030.0%18.022.00.045.0%38.022.00.063.3%
Book Value Change Per Share3.01.00.075.0%6.06.00.050.0%9.011.00.045.0%19.021.00.047.5%33.024.03.055.0%
Dividend per Share0.00.04.00.0%5.00.07.041.7%11.00.09.055.0%19.00.021.047.5%19.00.041.031.7%
Total Gains per Share3.01.00.075.0%6.06.00.050.0%9.011.00.045.0%19.021.00.047.5%33.024.03.055.0%

Fundamentals of Biotest

About Biotest Aktiengesellschaft

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

Fundamental data was last updated by Penke on 2024-04-10 00:20:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just not able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Biotest Aktiengesellschaft.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Biotest earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • A Net Profit Margin of 20.9% means that €0.21 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Biotest Aktiengesellschaft:

  • The MRQ is 20.9%. The company is making a huge profit. +2
  • The TTM is 15.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ20.9%TTM15.7%+5.2%
TTM15.7%YOY-6.7%+22.4%
TTM15.7%5Y-2.3%+18.0%
5Y-2.3%10Y156.0%-158.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ20.9%-200.1%+221.0%
TTM15.7%-216.8%+232.5%
YOY-6.7%-288.3%+281.6%
5Y-2.3%-449.1%+446.8%
10Y156.0%-605.5%+761.5%
1.1.2. Return on Assets

Shows how efficient Biotest is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • 2.7% Return on Assets means that Biotest generated €0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Biotest Aktiengesellschaft:

  • The MRQ is 2.7%. Using its assets, the company is less efficient in making profit.
  • The TTM is 2.8%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ2.7%TTM2.8%-0.1%
TTM2.8%YOY-0.7%+3.5%
TTM2.8%5Y0.0%+2.8%
5Y0.0%10Y0.0%-0.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7%-13.3%+16.0%
TTM2.8%-12.8%+15.6%
YOY-0.7%-11.7%+11.0%
5Y0.0%-13.9%+13.9%
10Y0.0%-15.7%+15.7%
1.1.3. Return on Equity

Shows how efficient Biotest is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • 7.7% Return on Equity means Biotest generated €0.08 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Biotest Aktiengesellschaft:

  • The MRQ is 7.7%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 8.2%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ7.7%TTM8.2%-0.4%
TTM8.2%YOY-2.2%+10.4%
TTM8.2%5Y0.0%+8.2%
5Y0.0%10Y0.2%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.7%-16.9%+24.6%
TTM8.2%-16.1%+24.3%
YOY-2.2%-15.1%+12.9%
5Y0.0%-19.3%+19.3%
10Y0.2%-20.2%+20.4%

1.2. Operating Efficiency of Biotest Aktiengesellschaft.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Biotest is operating .

  • Measures how much profit Biotest makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • An Operating Margin of 13.9% means the company generated €0.14  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Biotest Aktiengesellschaft:

  • The MRQ is 13.9%. The company is operating less efficient.
  • The TTM is 19.3%. The company is operating efficient. +1
Trends
Current periodCompared to+/- 
MRQ13.9%TTM19.3%-5.4%
TTM19.3%YOY-3.8%+23.0%
TTM19.3%5Y-0.3%+19.5%
5Y-0.3%10Y63.6%-63.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.9%-296.2%+310.1%
TTM19.3%-232.5%+251.8%
YOY-3.8%-298.2%+294.4%
5Y-0.3%-492.1%+491.8%
10Y63.6%-632.4%+696.0%
1.2.2. Operating Ratio

Measures how efficient Biotest is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.86 means that the operating costs are €0.86 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 0.861. The company is less efficient in keeping operating costs low.
  • The TTM is 0.807. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.861TTM0.807+0.054
TTM0.807YOY1.033-0.226
TTM0.8075Y0.994-0.186
5Y0.99410Y2.458-1.464
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8613.231-2.370
TTM0.8073.310-2.503
YOY1.0333.890-2.857
5Y0.9945.739-4.745
10Y2.4587.876-5.418

1.3. Liquidity of Biotest Aktiengesellschaft.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Biotest is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.96 means the company has €1.96 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 1.963. The company is able to pay all its short-term debts. +1
  • The TTM is 4.158. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ1.963TTM4.158-2.195
TTM4.158YOY4.532-0.374
TTM4.1585Y4.485-0.327
5Y4.48510Y4.142+0.343
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9633.890-1.927
TTM4.1584.173-0.015
YOY4.5325.344-0.812
5Y4.4856.126-1.641
10Y4.1426.448-2.306
1.3.2. Quick Ratio

Measures if Biotest is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • A Quick Ratio of 0.85 means the company can pay off €0.85 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 0.845. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.882. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.845TTM1.882-1.037
TTM1.882YOY2.291-0.409
TTM1.8825Y2.174-0.293
5Y2.17410Y1.840+0.335
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8453.514-2.669
TTM1.8823.998-2.116
YOY2.2915.380-3.089
5Y2.1746.105-3.931
10Y1.8406.404-4.564

1.4. Solvency of Biotest Aktiengesellschaft.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Biotest assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Biotest to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.65 means that Biotest assets are financed with 65.5% credit (debt) and the remaining percentage (100% - 65.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 0.655. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.678. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.655TTM0.678-0.023
TTM0.678YOY0.677+0.000
TTM0.6785Y0.627+0.051
5Y0.62710Y0.600+0.027
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6550.339+0.316
TTM0.6780.336+0.342
YOY0.6770.271+0.406
5Y0.6270.366+0.261
10Y0.6000.389+0.211
1.4.2. Debt to Equity Ratio

Measures if Biotest is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Biotest to the Biotechnology industry mean.
  • A Debt to Equity ratio of 189.5% means that company has €1.89 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Biotest Aktiengesellschaft:

  • The MRQ is 1.895. The company is just able to pay all its debts with equity.
  • The TTM is 2.117. The company is just not able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.895TTM2.117-0.222
TTM2.117YOY2.103+0.015
TTM2.1175Y1.733+0.385
5Y1.73310Y1.559+0.173
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8950.388+1.507
TTM2.1170.402+1.715
YOY2.1030.335+1.768
5Y1.7330.426+1.307
10Y1.5590.461+1.098

2. Market Valuation of Biotest Aktiengesellschaft

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Biotest generates.

  • Above 15 is considered overpriced but always compare Biotest to the Biotechnology industry mean.
  • A PE ratio of 7.95 means the investor is paying €7.95 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Biotest Aktiengesellschaft:

  • The EOD is 7.407. Based on the earnings, the company is cheap. +2
  • The MRQ is 7.945. Based on the earnings, the company is underpriced. +1
  • The TTM is 9.726. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD7.407MRQ7.945-0.538
MRQ7.945TTM9.726-1.781
TTM9.726YOY-25.050+34.776
TTM9.7265Y-25.056+34.782
5Y-25.05610Y-647.226+622.170
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.407-2.264+9.671
MRQ7.945-2.629+10.574
TTM9.726-2.680+12.406
YOY-25.050-4.145-20.905
5Y-25.056-6.257-18.799
10Y-647.226-6.254-640.972
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Biotest Aktiengesellschaft:

  • The EOD is 4.242. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 4.550. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 10.512. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD4.242MRQ4.550-0.308
MRQ4.550TTM10.512-5.961
TTM10.512YOY-6.412+16.924
TTM10.5125Y-39.901+50.413
5Y-39.90110Y-38.463-1.438
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.242-2.973+7.215
MRQ4.550-3.333+7.883
TTM10.512-3.553+14.065
YOY-6.412-5.605-0.807
5Y-39.901-8.376-31.525
10Y-38.463-8.865-29.598
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Biotest is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.46 means the investor is paying €2.46 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Biotest Aktiengesellschaft:

  • The EOD is 2.292. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.459. Based on the equity, the company is underpriced. +1
  • The TTM is 3.029. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.292MRQ2.459-0.167
MRQ2.459TTM3.029-0.570
TTM3.029YOY3.695-0.666
TTM3.0295Y2.697+0.332
5Y2.69710Y5.285-2.588
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.2921.896+0.396
MRQ2.4592.115+0.344
TTM3.0292.093+0.936
YOY3.6952.884+0.811
5Y2.6973.542-0.845
10Y5.2853.916+1.369
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Biotest Aktiengesellschaft compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.9860.747+32%-0.617+163%-0.001+100%0.028+3376%
Book Value Per Share--12.60810.635+19%9.449+33%11.312+11%11.016+14%
Current Ratio--1.9634.158-53%4.532-57%4.485-56%4.142-53%
Debt To Asset Ratio--0.6550.678-3%0.677-3%0.627+4%0.600+9%
Debt To Equity Ratio--1.8952.117-11%2.103-10%1.733+9%1.559+22%
Dividend Per Share----0%0.005-100%0.012-100%0.014-100%
Eps--0.9751.247-22%-0.079+108%0.074+1221%0.093+949%
Free Cash Flow Per Share--1.703-0.010+101%-0.449+126%-0.218+113%-0.341+120%
Free Cash Flow To Equity Per Share--1.410-0.053+104%0.131+976%0.031+4397%-0.206+115%
Gross Profit Margin--0.6270.884-29%0.452+39%0.285+120%4.618-86%
Intrinsic Value_10Y_max--100.640--------
Intrinsic Value_10Y_min--24.070--------
Intrinsic Value_1Y_max--1.072--------
Intrinsic Value_1Y_min---0.728--------
Intrinsic Value_3Y_max--10.091--------
Intrinsic Value_3Y_min--0.519--------
Intrinsic Value_5Y_max--27.390--------
Intrinsic Value_5Y_min--4.723--------
Market Cap571806730.000-115%1226715012.0001247490024.300-2%1336941461.800-8%1113700651.315+10%2388661496.005-49%
Net Profit Margin--0.2090.157+33%-0.067+132%-0.023+111%1.560-87%
Operating Margin--0.1390.193-28%-0.038+127%-0.003+102%0.636-78%
Operating Ratio--0.8610.807+7%1.033-17%0.994-13%2.458-65%
Pb Ratio2.292-7%2.4593.029-19%3.695-33%2.697-9%5.285-53%
Pe Ratio7.407-7%7.9459.726-18%-25.050+415%-25.056+415%-647.226+8246%
Price Per Share28.900-7%31.00031.525-2%34.875-11%29.318+6%61.465-50%
Price To Free Cash Flow Ratio4.242-7%4.55010.512-57%-6.412+241%-39.901+977%-38.463+945%
Price To Total Gains Ratio29.323-7%31.45414.880+111%-26.793+185%-34.176+209%-37.366+219%
Quick Ratio--0.8451.882-55%2.291-63%2.174-61%1.840-54%
Return On Assets--0.0270.028-5%-0.007+127%0.000+101%0.000+6125%
Return On Equity--0.0770.082-5%-0.022+129%0.000+100%0.002+3541%
Total Gains Per Share--0.9860.747+32%-0.611+162%0.011+8559%0.042+2228%
Usd Book Value--531627840.000448457760.000+19%385933680.000+38%455266944.000+17%453724488.000+17%
Usd Book Value Change Per Share--1.0500.795+32%-0.657+163%-0.001+100%0.030+3376%
Usd Book Value Per Share--13.43511.333+19%10.069+33%12.054+11%11.739+14%
Usd Dividend Per Share----0%0.006-100%0.013-100%0.015-100%
Usd Eps--1.0391.329-22%-0.084+108%0.079+1221%0.099+949%
Usd Free Cash Flow--71821440.000-426240.000+101%-18594720.000+126%-8903088.000+112%-14401584.000+120%
Usd Free Cash Flow Per Share--1.815-0.011+101%-0.479+126%-0.233+113%-0.364+120%
Usd Free Cash Flow To Equity Per Share--1.503-0.057+104%0.140+976%0.033+4397%-0.220+115%
Usd Market Cap609317251.488-115%1307187516.7871329325369.894-2%1424644821.694-8%1186759414.041+10%2545357690.143-49%
Usd Price Per Share30.796-7%33.03433.593-2%37.163-11%31.241+6%65.498-50%
Usd Profit--41132160.00041238720.0000%-8444880.000+121%1262736.000+3157%2496168.000+1548%
Usd Revenue--196390080.000189756720.000+3%137489040.000+43%141048144.000+39%137209320.000+43%
Usd Total Gains Per Share--1.0500.795+32%-0.652+162%0.012+8559%0.045+2228%
 EOD+4 -4MRQTTM+21 -13YOY+27 -95Y+27 -910Y+22 -14

3.2. Fundamental Score

Let's check the fundamental score of Biotest Aktiengesellschaft based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-157.407
Price to Book Ratio (EOD)Between0-12.292
Net Profit Margin (MRQ)Greater than00.209
Operating Margin (MRQ)Greater than00.139
Quick Ratio (MRQ)Greater than10.845
Current Ratio (MRQ)Greater than11.963
Debt to Asset Ratio (MRQ)Less than10.655
Debt to Equity Ratio (MRQ)Less than11.895
Return on Equity (MRQ)Greater than0.150.077
Return on Assets (MRQ)Greater than0.050.027
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Biotest Aktiengesellschaft based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.676
Ma 20Greater thanMa 5028.450
Ma 50Greater thanMa 10027.912
Ma 100Greater thanMa 20029.160
OpenGreater thanClose28.900
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets1,444,300
Total Liabilities945,400
Total Stockholder Equity498,900
 As reported
Total Liabilities 945,400
Total Stockholder Equity+ 498,900
Total Assets = 1,444,300

Assets

Total Assets1,444,300
Total Current Assets756,500
Long-term Assets687,800
Total Current Assets
Cash And Cash Equivalents 118,500
Short-term Investments 200
Net Receivables 206,800
Inventory 419,100
Other Current Assets 11,900
Total Current Assets  (as reported)756,500
Total Current Assets  (calculated)756,500
+/-0
Long-term Assets
Property Plant Equipment 578,400
Goodwill 6,000
Intangible Assets 9,000
Long-term Assets Other 200
Long-term Assets  (as reported)687,800
Long-term Assets  (calculated)593,600
+/- 94,200

Liabilities & Shareholders' Equity

Total Current Liabilities385,300
Long-term Liabilities560,100
Total Stockholder Equity498,900
Total Current Liabilities
Short-term Debt 260,100
Short Long Term Debt 226,800
Accounts payable 78,100
Other Current Liabilities 46,900
Total Current Liabilities  (as reported)385,300
Total Current Liabilities  (calculated)611,900
+/- 226,600
Long-term Liabilities
Long term Debt 329,500
Capital Lease Obligations 57,800
Long-term Liabilities Other -300
Long-term Liabilities  (as reported)560,100
Long-term Liabilities  (calculated)387,000
+/- 173,100
Total Stockholder Equity
Common Stock39,600
Retained Earnings 238,400
Accumulated Other Comprehensive Income 1,100
Other Stockholders Equity 219,800
Total Stockholder Equity (as reported)498,900
Total Stockholder Equity (calculated)498,900
+/-0
Other
Capital Stock39,600
Cash and Short Term Investments 118,700
Common Stock Shares Outstanding 39,571
Current Deferred Revenue200
Liabilities and Stockholders Equity 1,444,300
Net Debt 571,300
Net Invested Capital 1,055,200
Net Working Capital 371,200
Property Plant and Equipment Gross 962,400
Short Long Term Debt Total 689,800



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-31
> Total Assets 
0
0
0
633,454
636,900
656,100
640,500
632,339
637,900
680,800
721,900
682,762
689,500
688,200
672,800
682,347
663,800
745,800
746,500
886,500
902,500
914,300
932,100
1,032,600
1,072,200
1,052,200
962,800
962,700
968,300
981,900
962,400
932,800
889,200
967,100
953,600
978,500
1,017,200
1,334,900
1,047,500
1,042,300
1,044,600
1,058,200
1,091,000
1,108,400
1,107,600
1,145,200
1,122,200
1,131,300
1,134,800
1,145,800
1,135,400
1,104,200
1,109,800
1,101,900
1,079,300
1,203,000
1,190,200
1,214,100
1,349,500
1,444,300
1,444,3001,349,5001,214,1001,190,2001,203,0001,079,3001,101,9001,109,8001,104,2001,135,4001,145,8001,134,8001,131,3001,122,2001,145,2001,107,6001,108,4001,091,0001,058,2001,044,6001,042,3001,047,5001,334,9001,017,200978,500953,600967,100889,200932,800962,400981,900968,300962,700962,8001,052,2001,072,2001,032,600932,100914,300902,500886,500746,500745,800663,800682,347672,800688,200689,500682,762721,900680,800637,900632,339640,500656,100636,900633,454000
   > Total Current Assets 
0
0
0
325,261
326,300
333,200
309,800
308,944
324,800
372,100
412,400
369,950
385,600
374,100
360,100
367,461
346,900
430,400
425,900
562,500
559,700
584,700
594,500
679,300
697,300
649,500
595,300
586,800
565,600
554,100
503,300
467,200
392,000
396,500
368,800
449,700
487,600
793,600
500,300
495,100
476,100
488,600
508,500
522,800
525,600
563,900
542,200
556,300
560,600
570,500
556,600
522,200
523,900
522,000
497,500
619,400
597,400
620,700
736,200
756,500
756,500736,200620,700597,400619,400497,500522,000523,900522,200556,600570,500560,600556,300542,200563,900525,600522,800508,500488,600476,100495,100500,300793,600487,600449,700368,800396,500392,000467,200503,300554,100565,600586,800595,300649,500697,300679,300594,500584,700559,700562,500425,900430,400346,900367,461360,100374,100385,600369,950412,400372,100324,800308,944309,800333,200326,300325,261000
       Cash And Cash Equivalents 
0
0
0
6,730
12,200
6,800
9,500
18,541
7,300
6,100
120,000
83,199
70,100
58,900
55,500
57,241
32,300
97,300
70,700
204,400
174,200
89,800
79,500
179,400
125,000
96,800
88,300
53,800
120,500
114,400
88,200
72,900
38,100
62,800
30,900
22,300
42,700
165,700
119,600
61,900
43,400
49,800
65,500
60,800
44,000
63,700
40,200
71,300
55,000
72,000
79,200
104,400
115,300
85,000
53,300
116,600
68,000
58,300
65,400
118,500
118,50065,40058,30068,000116,60053,30085,000115,300104,40079,20072,00055,00071,30040,20063,70044,00060,80065,50049,80043,40061,900119,600165,70042,70022,30030,90062,80038,10072,90088,200114,400120,50053,80088,30096,800125,000179,40079,50089,800174,200204,40070,70097,30032,30057,24155,50058,90070,10083,199120,0006,1007,30018,5419,5006,80012,2006,730000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
54,700
0
0
0
99,900
50,500
51,800
41,800
10,000
10,800
1,600
1,100
5,900
128,900
295,300
36,800
44,200
52,500
31,900
34,100
24,900
20,600
31,000
32,800
17,900
13,300
13,100
12,100
13,100
14,800
18,100
23,600
20,000
18,900
12,600
13,400
200
20013,40012,60018,90020,00023,60018,10014,80013,10012,10013,10013,30017,90032,80031,00020,60024,90034,10031,90052,50044,20036,800295,300128,9005,9001,1001,60010,80010,00041,80051,80050,50099,90000054,70000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
180,900
128,400
148,200
153,200
152,500
139,900
155,800
144,300
196,700
94,200
108,400
104,800
167,100
139,000
156,500
152,600
179,200
171,800
168,900
155,100
160,800
120,000
140,300
128,300
185,900
162,500
193,400
254,500
206,800
206,800254,500193,400162,500185,900128,300140,300120,000160,800155,100168,900171,800179,200152,600156,500139,000167,100104,800108,40094,200196,700144,300155,800139,900152,500153,200148,200128,400180,9000000000000000000000000000000000
       Other Current Assets 
0
0
0
148,205
146,100
156,000
132,400
141,692
172,400
220,200
132,200
133,768
147,800
137,500
127,100
126,004
120,600
122,300
132,200
131,100
138,500
231,200
247,500
199,200
320,700
309,100
280,900
214,400
186,300
184,700
186,500
213,500
175,900
161,400
166,900
274,600
150,900
166,600
164,300
180,700
144,200
159,900
151,600
157,000
148,600
164,900
162,300
177,000
190,500
182,300
167,200
160,100
18,000
15,400
23,600
3,100
20,400
15,300
29,300
11,900
11,90029,30015,30020,4003,10023,60015,40018,000160,100167,200182,300190,500177,000162,300164,900148,600157,000151,600159,900144,200180,700164,300166,600150,900274,600166,900161,400175,900213,500186,500184,700186,300214,400280,900309,100320,700199,200247,500231,200138,500131,100132,200122,300120,600126,004127,100137,500147,800133,768132,200220,200172,400141,692132,400156,000146,100148,205000
   > Long-term Assets 
0
0
0
308,193
310,600
322,900
330,700
323,395
313,100
308,700
309,500
312,812
303,900
314,100
312,700
314,886
316,900
315,400
320,600
324,000
342,800
329,600
337,600
353,300
374,900
402,700
367,500
375,900
402,700
427,800
459,100
465,600
497,200
570,600
584,800
528,800
529,600
541,300
547,200
547,200
568,500
569,600
582,500
585,600
582,000
581,300
580,000
575,000
574,200
575,300
578,800
582,000
585,900
579,900
581,800
583,600
592,700
593,400
613,300
687,800
687,800613,300593,400592,700583,600581,800579,900585,900582,000578,800575,300574,200575,000580,000581,300582,000585,600582,500569,600568,500547,200547,200541,300529,600528,800584,800570,600497,200465,600459,100427,800402,700375,900367,500402,700374,900353,300337,600329,600342,800324,000320,600315,400316,900314,886312,700314,100303,900312,812309,500308,700313,100323,395330,700322,900310,600308,193000
       Property Plant Equipment 
0
0
0
231,955
217,500
226,800
235,800
230,749
224,300
222,600
226,200
234,857
232,400
241,600
240,100
244,576
244,900
244,300
249,400
254,900
254,500
257,100
266,200
282,300
297,300
307,200
282,300
317,200
341,000
367,800
397,900
414,900
436,700
455,700
475,500
477,100
487,900
500,700
507,100
512,700
533,100
531,600
541,800
547,900
545,000
546,100
546,000
548,200
547,200
546,600
547,400
550,000
547,800
544,600
543,800
547,800
549,600
555,700
573,400
578,400
578,400573,400555,700549,600547,800543,800544,600547,800550,000547,400546,600547,200548,200546,000546,100545,000547,900541,800531,600533,100512,700507,100500,700487,900477,100475,500455,700436,700414,900397,900367,800341,000317,200282,300307,200297,300282,300266,200257,100254,500254,900249,400244,300244,900244,576240,100241,600232,400234,857226,200222,600224,300230,749235,800226,800217,500231,955000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,137
0
0
0
28,800
0
0
0
32,700
0
0
0
36,500
0
0
0
16,800
0
0
0
7,300
0
0
0
7,200
0
0
0
7,200
0
0
0
7,100
0
0
0
7,100
0
0
0
7,200
0
0
0
6,000
6,0000007,2000007,1000007,1000007,2000007,2000007,30000016,80000036,50000032,70000028,80000030,137000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,300
5,800
55,500
47,100
2,300
2,700
2,500
2,500
1,900
9,600
12,500
11,900
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000011,90012,5009,6001,9002,5002,5002,7002,30047,10055,5005,8004,3000000000000000000000000000000000
       Intangible Assets 
0
0
0
66,680
68,700
72,100
64,700
64,941
64,000
62,200
63,400
62,833
59,600
60,600
0
22,918
0
0
0
19,300
0
0
0
17,500
0
0
0
8,200
0
0
0
8,500
24,800
24,100
24,300
9,300
16,200
16,200
16,400
9,200
17,000
16,800
13,900
6,600
0
0
0
6,900
0
0
0
4,100
0
0
0
9,200
20,700
15,500
15,800
9,000
9,00015,80015,50020,7009,2000004,1000006,9000006,60013,90016,80017,0009,20016,40016,20016,2009,30024,30024,10024,8008,5000008,20000017,50000019,30000022,918060,60059,60062,83363,40062,20064,00064,94164,70072,10068,70066,680000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
243,900
29,900
35,300
37,900
216,500
22,800
21,900
21,200
227,200
8,800
8,700
14,900
251,600
13,600
12,000
11,400
249,700
10,700
12,600
15,300
90,400
22,200
19,700
21,300
0
100
17,100
0
0
0017,100100021,30019,70022,20090,40015,30012,60010,700249,70011,40012,00013,600251,60014,9008,7008,800227,20021,20021,90022,800216,50037,90035,30029,900243,9000000000000000000000000000000000
> Total Liabilities 
0
0
0
363,592
339,200
347,600
339,800
324,731
329,300
372,900
382,100
336,094
341,400
334,300
315,400
312,914
285,200
293,000
290,200
425,800
436,800
446,200
445,300
552,400
569,300
568,200
564,600
550,400
558,200
565,200
555,400
572,100
553,300
627,600
622,200
630,700
677,100
835,900
542,200
547,100
550,700
562,000
599,300
631,500
641,400
685,900
678,000
689,700
707,100
723,400
723,200
723,800
734,700
743,200
735,500
831,900
839,100
840,600
889,600
945,400
945,400889,600840,600839,100831,900735,500743,200734,700723,800723,200723,400707,100689,700678,000685,900641,400631,500599,300562,000550,700547,100542,200835,900677,100630,700622,200627,600553,300572,100555,400565,200558,200550,400564,600568,200569,300552,400445,300446,200436,800425,800290,200293,000285,200312,914315,400334,300341,400336,094382,100372,900329,300324,731339,800347,600339,200363,592000
   > Total Current Liabilities 
0
0
0
148,777
119,700
122,200
120,700
131,348
140,300
153,000
162,700
147,735
159,700
153,100
141,400
164,877
137,800
148,200
147,500
124,300
121,000
131,100
129,700
128,900
132,500
131,000
129,500
125,800
125,200
135,600
128,200
146,000
118,500
135,100
136,500
251,200
385,000
381,400
131,100
125,600
107,800
415,600
101,100
115,000
123,100
113,800
103,300
105,600
121,100
111,100
103,800
106,400
114,900
122,200
109,600
130,200
129,500
122,800
147,200
385,300
385,300147,200122,800129,500130,200109,600122,200114,900106,400103,800111,100121,100105,600103,300113,800123,100115,000101,100415,600107,800125,600131,100381,400385,000251,200136,500135,100118,500146,000128,200135,600125,200125,800129,500131,000132,500128,900129,700131,100121,000124,300147,500148,200137,800164,877141,400153,100159,700147,735162,700153,000140,300131,348120,700122,200119,700148,777000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
41,445
32,400
32,500
29,900
5,300
5,400
5,600
7,300
6,100
7,700
10,100
10,800
9,100
9,700
15,000
17,200
16,200
17,200
17,900
23,900
119,600
269,900
254,800
34,300
700
2,400
302,500
6,900
7,300
5,900
8,100
32,800
7,900
0
0
0
34,300
0
0
0
9,400
32,000
33,600
43,800
260,100
260,10043,80033,60032,0009,40000034,3000007,90032,8008,1005,9007,3006,900302,5002,40070034,300254,800269,900119,60023,90017,90017,20016,20017,20015,0009,7009,10010,80010,1007,7006,1007,3005,6005,4005,30029,90032,50032,40041,445000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
346,200
350,500
414,300
23,900
119,400
269,900
254,800
34,300
500
2,400
302,500
6,900
3,300
0
0
0
3,500
0
0
0
29,500
0
0
0
4,800
0
0
0
226,800
226,8000004,80000029,5000003,5000003,3006,900302,5002,40050034,300254,800269,900119,40023,900414,300350,500346,2000000000000000000000000000000000
       Accounts payable 
0
0
0
40,583
38,100
41,600
46,900
42,779
33,900
39,700
42,500
34,678
39,600
48,200
41,400
47,373
39,500
50,900
46,900
51,400
44,800
58,000
52,200
55,500
54,300
55,000
56,200
53,100
51,800
57,800
47,500
62,800
43,500
56,000
49,400
65,000
41,600
72,300
45,400
73,400
50,600
63,300
40,100
52,200
54,700
49,000
37,700
42,000
49,300
43,800
31,500
38,800
38,700
42,200
30,200
51,100
44,700
54,500
53,300
78,100
78,10053,30054,50044,70051,10030,20042,20038,70038,80031,50043,80049,30042,00037,70049,00054,70052,20040,10063,30050,60073,40045,40072,30041,60065,00049,40056,00043,50062,80047,50057,80051,80053,10056,20055,00054,30055,50052,20058,00044,80051,40046,90050,90039,50047,37341,40048,20039,60034,67842,50039,70033,90042,77946,90041,60038,10040,583000
       Other Current Liabilities 
0
0
0
108,194
81,600
80,600
73,800
88,569
106,400
113,300
120,200
113,057
120,100
104,900
100,000
76,059
65,900
64,800
70,700
67,600
70,800
67,500
70,200
67,300
70,500
65,900
62,500
63,600
63,700
62,800
63,500
67,000
57,800
61,200
63,200
66,600
73,500
54,300
51,400
51,500
54,800
49,800
54,100
55,500
62,500
56,700
65,600
55,700
71,800
67,300
71,600
32,000
76,200
80,000
79,400
69,500
52,600
34,500
49,900
46,900
46,90049,90034,50052,60069,50079,40080,00076,20032,00071,60067,30071,80055,70065,60056,70062,50055,50054,10049,80054,80051,50051,40054,30073,50066,60063,20061,20057,80067,00063,50062,80063,70063,60062,50065,90070,50067,30070,20067,50070,80067,60070,70064,80065,90076,059100,000104,900120,100113,057120,200113,300106,40088,56973,80080,60081,600108,194000
   > Long-term Liabilities 
0
0
0
214,815
219,500
225,400
219,100
193,383
189,000
219,900
219,400
188,359
181,700
181,200
174,000
148,037
147,400
144,800
142,700
301,500
315,800
315,100
315,600
423,500
436,800
437,200
435,100
424,600
433,000
429,600
427,200
426,100
434,800
492,500
485,700
379,500
292,100
454,500
411,100
421,500
442,900
146,400
498,200
516,500
518,300
572,100
574,700
584,100
586,000
612,300
619,400
617,400
619,800
621,000
625,900
701,700
709,600
717,800
742,400
560,100
560,100742,400717,800709,600701,700625,900621,000619,800617,400619,400612,300586,000584,100574,700572,100518,300516,500498,200146,400442,900421,500411,100454,500292,100379,500485,700492,500434,800426,100427,200429,600433,000424,600435,100437,200436,800423,500315,600315,100315,800301,500142,700144,800147,400148,037174,000181,200181,700188,359219,400219,900189,000193,383219,100225,400219,500214,815000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
96,100
101,500
96,100
97,200
92,700
90,700
93,800
92,300
92,800
92,600
94,100
94,400
113,600
112,400
112,900
114,100
121,600
122,300
122,700
123,100
121,000
121,700
120,900
625,900
0
0
89,300
0
0
0089,30000625,900120,900121,700121,000123,100122,700122,300121,600114,100112,900112,400113,60094,40094,10092,60092,80092,30093,80090,70092,70097,20096,100101,50096,1000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000001000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
264,761
292,000
302,200
293,700
301,564
301,700
302,100
339,700
346,572
348,000
353,800
357,300
369,324
378,500
452,700
456,200
460,600
465,600
468,000
486,700
480,100
502,800
483,900
398,100
412,200
409,900
416,600
406,900
360,500
335,700
339,300
331,200
347,600
339,900
498,800
505,100
495,000
493,900
496,200
491,700
476,900
466,200
459,300
444,200
441,600
427,700
422,400
412,200
380,400
375,100
358,700
343,800
371,100
351,100
373,500
459,900
498,900
498,900459,900373,500351,100371,100343,800358,700375,100380,400412,200422,400427,700441,600444,200459,300466,200476,900491,700496,200493,900495,000505,100498,800339,900347,600331,200339,300335,700360,500406,900416,600409,900412,200398,100483,900502,800480,100486,700468,000465,600460,600456,200452,700378,500369,324357,300353,800348,000346,572339,700302,100301,700301,564293,700302,200292,000264,761000
   Common Stock
0
0
0
30,025
30,000
30,000
30,000
30,025
30,000
30,000
30,000
30,025
30,000
30,000
30,000
30,025
30,000
33,800
33,800
33,800
33,800
33,800
33,800
33,800
33,800
33,800
33,800
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,600
39,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60039,60033,80033,80033,80033,80033,80033,80033,80033,80033,80033,80030,00030,02530,00030,00030,00030,02530,00030,00030,00030,02530,00030,00030,00030,025000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
-157,410
0
0
0
-163,520
0
0
0
-184,904
0
0
0
-182,874
0
0
0
-203,200
0
0
0
-223,700
0
0
0
-309,100
0
0
0
-217,500
0
0
0
-226,400
0
0
0
-249,200
0
0
0
-271,700
0
0
0
-295,400
0
0
0
0
0
0
0
-2,000
0
0
0
1,100
1,100000-2,0000000000-295,400000-271,700000-249,200000-226,400000-217,500000-309,100000-223,700000-203,200000-182,874000-184,904000-163,520000-157,410000
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
209,063
262,000
243,700
234,700
234,592
266,800
260,300
271,000
270,194
314,200
313,900
311,700
305,891
153,300
225,600
225,600
208,700
225,600
225,600
225,600
208,700
225,600
225,600
225,600
200,000
219,800
219,800
369,000
219,800
219,800
219,800
219,800
200,000
219,800
219,800
219,800
200,000
219,800
200,000
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800
219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800219,800200,000219,800200,000219,800219,800219,800200,000219,800219,800219,800219,800369,000219,800219,800200,000225,600225,600225,600208,700225,600225,600225,600208,700225,600225,600153,300305,891311,700313,900314,200270,194271,000260,300266,800234,592234,700243,700262,000209,063000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue684,600
Cost of Revenue-412,700
Gross Profit271,900271,900
 
Operating Income (+$)
Gross Profit271,900
Operating Expense-141,700
Operating Income130,200130,200
 
Operating Expense (+$)
Research Development66,200
Selling General Administrative30,600
Selling And Marketing Expenses50,400
Operating Expense141,700147,200
 
Net Interest Income (+$)
Interest Income3,600
Interest Expense-40,000
Other Finance Cost-3,900
Net Interest Income-40,300
 
Pretax Income (+$)
Operating Income130,200
Net Interest Income-40,300
Other Non-Operating Income Expenses0
Income Before Tax (EBT)106,300154,100
EBIT - interestExpense = 90,200
106,300
167,000
Interest Expense40,000
Earnings Before Interest and Taxes (EBIT)130,200146,300
Earnings Before Interest and Taxes (EBITDA)166,100
 
After tax Income (+$)
Income Before Tax106,300
Tax Provision-5,100
Net Income From Continuing Ops90,900101,200
Net Income127,000
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses554,400
Total Other Income/Expenses Net-23,90040,300
 

Technical Analysis of Biotest
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biotest. The general trend of Biotest is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biotest's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Biotest Aktiengesellschaft.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 29.90 < 30.20 < 30.40.

The bearish price targets are: 27.40 > 22.80.

Tweet this
Biotest Aktiengesellschaft Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Biotest Aktiengesellschaft. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Biotest Aktiengesellschaft Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Biotest Aktiengesellschaft. The current macd is 0.34252994.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Biotest price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Biotest. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Biotest price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Biotest Aktiengesellschaft Daily Moving Average Convergence/Divergence (MACD) ChartBiotest Aktiengesellschaft Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Biotest Aktiengesellschaft. The current adx is 20.75.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Biotest shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Biotest Aktiengesellschaft Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Biotest Aktiengesellschaft. The current sar is 28.37.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Biotest Aktiengesellschaft Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Biotest Aktiengesellschaft. The current rsi is 57.68. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Biotest Aktiengesellschaft Daily Relative Strength Index (RSI) ChartBiotest Aktiengesellschaft Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Biotest Aktiengesellschaft. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biotest price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Biotest Aktiengesellschaft Daily Stochastic Oscillator ChartBiotest Aktiengesellschaft Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Biotest Aktiengesellschaft. The current cci is 46.46.

Biotest Aktiengesellschaft Daily Commodity Channel Index (CCI) ChartBiotest Aktiengesellschaft Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Biotest Aktiengesellschaft. The current cmo is 20.47.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Biotest Aktiengesellschaft Daily Chande Momentum Oscillator (CMO) ChartBiotest Aktiengesellschaft Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Biotest Aktiengesellschaft. The current willr is -66.66666667.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Biotest is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Biotest Aktiengesellschaft Daily Williams %R ChartBiotest Aktiengesellschaft Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Biotest Aktiengesellschaft.

Biotest Aktiengesellschaft Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Biotest Aktiengesellschaft. The current atr is 0.52319928.

Biotest Aktiengesellschaft Daily Average True Range (ATR) ChartBiotest Aktiengesellschaft Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Biotest Aktiengesellschaft. The current obv is 182,626.

Biotest Aktiengesellschaft Daily On-Balance Volume (OBV) ChartBiotest Aktiengesellschaft Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Biotest Aktiengesellschaft. The current mfi is 37.83.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Biotest Aktiengesellschaft Daily Money Flow Index (MFI) ChartBiotest Aktiengesellschaft Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Biotest Aktiengesellschaft.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-18RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-19ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside

6.3. Candlestick Patterns

Biotest Aktiengesellschaft Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Biotest Aktiengesellschaft based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.676
Ma 20Greater thanMa 5028.450
Ma 50Greater thanMa 10027.912
Ma 100Greater thanMa 20029.160
OpenGreater thanClose28.900
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Biotest with someone you think should read this too:
  • Are you bullish or bearish on Biotest? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Biotest? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Biotest Aktiengesellschaft

I send you an email if I find something interesting about Biotest Aktiengesellschaft.


Comments

How you think about this?

Leave a comment

Stay informed about Biotest Aktiengesellschaft.

Receive notifications about Biotest Aktiengesellschaft in your mailbox!